TY - JOUR
T1 - Characteristics of sweet syndrome in patients with acute myeloid leukemia
AU - Kazmi, Syed M.
AU - Pemmaraju, Naveen
AU - Patel, Keyur P.
AU - Cohen, Philip R.
AU - Daver, Naval
AU - Tran, Kathy M.
AU - Ravandi, Farhad
AU - Duvic, Madeleine
AU - Garcia-Manero, Guillermo
AU - Pierce, Sherry
AU - Nazha, Aziz
AU - Borthakur, Gautam
AU - Kantarjian, Hagop
AU - Cortes, Jorge
N1 - Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Introduction Sweet syndrome (SS) is associated with hematologic malignancies including acute myeloid leukemia (AML). Patients and Methods Records of patients with AML treated at our institution were reviewed to identify those with SS. Patient characteristics, laboratory values, and cytogenetic and molecular abnormalities were retrospectively reviewed. Results We identified 21 of 2178 (1%) AML patients who demonstrated clinical signs and symptoms, and histological features consistent with SS. Eleven patients (52%) were classified as AML with myelodysplasia-related features and 3 patients had therapy-related AML. Three patients had received treatment with granulocyte colony stimulation factor, 1 patient liposomal all-trans-retinoic acid, and 2 patients received hypomethylating agents before development of SS. Cytogenetic analysis revealed diploid karyotype in 7 patients (33%); -5/del(5q) in 8 patients (38%): 3 patients had -5/del(5q) as the sole abnormality and 5 patients had -5/del(5q) as part of complex cytogenetics; and complex cytogenetics in 5 patients (24%). Gene mutations in FMS-related tyrosine kinase-3 (FLT3) gene were identified in 7 of 18 evaluable patients (39%), including FLT3-internal tandem duplication in 4 patients and FLT3-D835 tyrosine kinase domain mutation in 3 patients. Conclusion SS occurs in 1% of AML patients; -5/del(5q) karyotype, FLT3 mutations, and AML with myelodysplasia-related features were more frequent among patients with SS.
AB - Introduction Sweet syndrome (SS) is associated with hematologic malignancies including acute myeloid leukemia (AML). Patients and Methods Records of patients with AML treated at our institution were reviewed to identify those with SS. Patient characteristics, laboratory values, and cytogenetic and molecular abnormalities were retrospectively reviewed. Results We identified 21 of 2178 (1%) AML patients who demonstrated clinical signs and symptoms, and histological features consistent with SS. Eleven patients (52%) were classified as AML with myelodysplasia-related features and 3 patients had therapy-related AML. Three patients had received treatment with granulocyte colony stimulation factor, 1 patient liposomal all-trans-retinoic acid, and 2 patients received hypomethylating agents before development of SS. Cytogenetic analysis revealed diploid karyotype in 7 patients (33%); -5/del(5q) in 8 patients (38%): 3 patients had -5/del(5q) as the sole abnormality and 5 patients had -5/del(5q) as part of complex cytogenetics; and complex cytogenetics in 5 patients (24%). Gene mutations in FMS-related tyrosine kinase-3 (FLT3) gene were identified in 7 of 18 evaluable patients (39%), including FLT3-internal tandem duplication in 4 patients and FLT3-D835 tyrosine kinase domain mutation in 3 patients. Conclusion SS occurs in 1% of AML patients; -5/del(5q) karyotype, FLT3 mutations, and AML with myelodysplasia-related features were more frequent among patients with SS.
KW - -5/del(5q)
KW - Acute febrile neutrophilic dermatosis
KW - FMS-related tyrosine kinase-3
KW - Myelodysplastic syndrome
KW - Neutrophilic dermatosis
UR - http://www.scopus.com/inward/record.url?scp=84931050305&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931050305&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2014.12.009
DO - 10.1016/j.clml.2014.12.009
M3 - Article
C2 - 25630528
AN - SCOPUS:84931050305
SN - 2152-2650
VL - 15
SP - 358
EP - 363
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 6
ER -